Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

New England Journal of Medicine

Volumn 349, Issue 1, 2003, Pages 17-26

  Tallman, Martin S ^a   Gray, Robert ^g   Robert, Nicholas J ^b   LeMaistre, Charles F ^c   Osborne, C Kent ^g   Vaughan, William P ^d   Gradishar, William J ^a   Pisansky, Thomas M ^e   Fetting, John ^g   Paietta, Elisabeth ^f   Lazarus, Hillard M ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c TEXAS TRANSPLANT INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MAYO CLINIC   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SKIN DISEASE; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; TAMOXIFEN; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0038374990     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030684     Document Type: Article

References (36)

1. Bonadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985;3:259-75.
2. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
3. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol 1987;10:387-95.
4. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-8. [Erratum, N Engl J Med 1994;330:1467.]
5. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-40.
6. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
7. Somlo G, Doroshow JH, Forman SJ, et al. High-dose chemotherapy and stem cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997;15:2882-93.
8. Gianni A, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer within 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997;15:2312-21.
9. Tomas JF, Perez-Carrion R, Escudero A, Lopez-Lorenzo JL, Lopez-Pascual J, Fenandez-Ranada JM. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 1997;19:331-6.
10. Schulze R, Schulze M, Wischnik A, et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant 1997;19:1223-8.
11. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-9.
12. Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med 1996;125:599-604.
13. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997;15:3178-84.
14. Bull JM, Tormey DC, Li SH, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41:1649-57.
15. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991;83:920-6.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Cox DR, Regression models and lifetables. J R Stat Soc [B] 1972;34:187-202.
19. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for highrisk primary breast carcinoma. J Natl Cancer Inst 2000;92:225-33.
20. Kodenhuis S, Richel DJ, van der Wall E, et al. A randomized trial of high-dose chemotherapy and haematopoietic progenitorcell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21.
21. Rodenhuis S, Bontenbal M, Beex LVAM, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-16.
22. Peters WP, Rosner G, Vredenburgh J, et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. Prog Proc Am Soc Clin Oncol 2001;20:21a. abstract.
23. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. ProgProc Am Soc Clin Oncol 1999;18:2a. abstract.
24. Crown JP, Lind M, Gould A, et al. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate, and 5-FU (CMF) following doxotubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study. Prog Proc Am Soc Clin Oncol 2002;21:42a. abstract.
25. Roche HH, Pouillart P, Meyer N, et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the Pegase 01 trial. Prog Proc Am Soc Clin Oncol 2001;20:26a. abstract.
26. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-10.
27. Kleinman MB, Wiley EL, Guo M, et al. Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. Bone Marrow Transplant 1999;23:1297-301.
28. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995;13:1557-63.
29. Roman-Unfer S, Bitran JD, Hanauer S, et al. Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant 1995;16:163-8.
30. Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000;18:2836-42.
31. Ando M, Narabayashi M, Watanabe T, et al. Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. Jpn J Clin Oncol 1999;29:28-32.
32. Laughlin MJ, McGaughey DS, Crews JR, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998;16:1008-12.
33. Nichols G, de Castro K, Wei L-X, et al. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia 2002;16:1673-9.
34. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after highdose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273-9. [Erratum, Blood 2000;96:1680.]
35. Metayer C, Curtis PE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-23.
36. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999;94:1814-9.